Discovery of novel analgesic and anti-inflammatory 3-arylamine-imidazo[1,2- a]pyridine symbiotic prototypes

We describe herein the discovery of LASSBio-1135 ( 3a) as a novel in vivo antinociceptive and anti-inflammatory symbiotic prototype that act as selective PGHS-2 inhibitor and p38 MAPK pathway modulator. We describe herein the design, synthesis and pharmacological evaluation of novel 3-arylamine-imid...

Full description

Saved in:
Bibliographic Details
Published in:Bioorganic & medicinal chemistry 2009, Vol.17 (1), p.74-84
Main Authors: Lacerda, Renata B., de Lima, Cleverton K.F., da Silva, Leandro L., Romeiro, Nelilma C., Miranda, Ana Luisa P., Barreiro, Eliezer J., Fraga, Carlos A.M.
Format: Article
Language:English
Subjects:
3-Arylamine-imidazo[1,2- a]pyridines
Analgesic
Analgesics
Analgesics - chemical synthesis
Analgesics - pharmacology
Animals
Anti-inflammatory
Anti-Inflammatory Agents - chemical synthesis
Anti-Inflammatory Agents - pharmacology
Biological and medical sciences
Bones, joints and connective tissue. Antiinflammatory agents
Cell Line
Cyclooxygenase 2 Inhibitors - chemical synthesis
Cyclooxygenase 2 Inhibitors - pharmacology
Disease Models, Animal
Drug Design
Drug Discovery
Edema - drug therapy
Humans
Hyperalgesia - drug therapy
Medical sciences
Neuropharmacology
p38 MAPK
Pharmacology. Drug treatments
Pyridines - chemical synthesis
Pyridines - pharmacology
Rats
Symbiotic drugs
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We describe herein the discovery of LASSBio-1135 ( 3a) as a novel in vivo antinociceptive and anti-inflammatory symbiotic prototype that act as selective PGHS-2 inhibitor and p38 MAPK pathway modulator. We describe herein the design, synthesis and pharmacological evaluation of novel 3-arylamine-imidazo[1,2- a]pyridine derivatives structurally designed as novel symbiotic prototypes presenting analgesic and anti-inflammatory properties. The derivatives obtained were submitted to in vivo assays of nociception, hyperalgesia and inflammation, and to in vitro assays of human PGHS-2 inhibition. These assays allowed the identification of compound LASSBio-1135 ( 3a) as an anti-inflammatory and analgesic symbiotic prototype. This compound inhibited moderately the human PGHS-2 enzyme activity (IC 50 = 18.5 μM) and reverted the capsaicin-induced thermal hyperalgesia (100 μmol/kg, po) similarly to p38 MAPK inhibitor SB-203580 ( 2). Additionally, LASSBio-1135 ( 3a) presented activity similar to celecoxib ( 1) regarding the reduction of the carrageenan-induced rat paw edema (33% of inhibition at 100 μmol/kg, po). We also discovered derivatives LASSBio-1140 ( 3c) and LASSBio-1141 ( 3e) as analgesic and anti-inflammatory prototypes, which were able to attenuate the capsaicin-induced thermal hyperalgesia (100 μmol/kg, po) and reduce the carrageenan-induced paw edema (ED 50 = 11.5 μmol/kg (3.3 mg/kg) and 14.5 μmol/kg (4.1 mg/kg), respectively), being both more active than celecoxib ( 1), despite the fact that their effects involve a different mechanism of action. Additionally, derivative LASSBio-1145 ( 3j) showed remarkable analgesic (ED 50 = 22.7 μmol/kg (8.9 mg/kg)) and anti-inflammatory (ED 50 = 8.7 μmol/kg (3.4 mg/kg)) profile in vivo (100 μmol/kg; po), in AcOH-induced abdominal constrictions in mice and carrageenan-induced rat paw edema models, respectively, being a novel orally-active anti-inflammatory drug candidate that acts as a selective PGHS-2 inhibitor (IC 50 = 2.8 μM).
ISSN:0968-0896
1464-3391
DOI:10.1016/j.bmc.2008.11.018